Medical Industry ReportsGlobal Drug Delivery Market - Trends and Forecast to 2022

  • RnM954725
  • |
  • 1 November, 2016
  • |
  • Global
  • |
  • 775 pages
  • |
  • DATABRIDGEMARKETRESEARCH
  • |
  • Medical Industry Reports

1 INTRODUCTION
1.1. OVERVIEW OF THE DRUG DELIVERY DEVICES MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED
2 RESEARCH METHODOLOGY
2.1. MARKETS IN DRUG DELIVERY DEVICES MARKET
2.2. GEOGRAPHICAL SCOPE
2.3. YEARS CONSIDERED IN THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.5.1. MARKET CRACKDOWN APPROACH
2.5.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.5.3. DATA TRIANGULATION
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS
3 MARKET OVERVIEW
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. ORAL DRUG DELIVERY, BY FORM
6.2.1. SOLID ORAL DRUGS, BY PRODUCT TYPE
6.2.2.1. TABLETS
6.2.2.2. CAPSULES
6.2.2.3. POWDER
6.2.2.4. PILLS
6.2.2. LIQUID ORAL DRUGS, BY PRODUCT TYPE
6.2.2.1. SOLUTIONS
6.2.2.2. SYRUPS
6.2.2. SEMI SOLID ORAL DRUGS, BY PRODUCT TYPE
6.2.2.1. GELS
6.2.2.2. EMULSIONS
6.2.2.3. ELIXIRS
6.3. PULMONARY DRUG DELIVERY, BY PRODUCT TYPE
6.3.1. METERED DOSE INHALERS (MDI)
6.3.2. DRY POWDER INHALERS (DPI)
6.3.3. NEBULIZERS
6.3.3.1. JET NEBULIZERS
6.3.3.2. ULTRASONIC NEBULIZERS
6.3.3.3. SOFT MIST NEBULIZERS
6.4. INJECTABLE DRUG DELIVERY, BY PRODUCT TYPE
6.4.1. INJECTABLE DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.4.1.1. CONVENTIONALS INJECTABLES, BY MATERIAL
6.4.1.1.1. GLASS
6.4.1.1.2. PLASTIC
6.4.2.2. CONVENTIONALS INJECTABLES, BY PRODUCT TYPE
6.4.2.2.1. FILLABLE
6.4.2.2.2. PRE-FILLED
6.4.3.3. CONVENTIONALS INJECTABLES, BY USABILITY
6.4.3.3.1. REUSABLE SYRIGES
6.4.3.3.2. DISPOSABLE SYRINGES
6.4.3.4. SELF INJECTION DEVICES
6.4.3.5. NEEDLE FREE INJECTORS
6.4.3.6. AUTOINJECTORS
6.4.3.7. PEN INJECTORS
6.4.3.8. WEARABLE INJCTORS
6.4.3.9. OTHERS
6.4.2. INJECTABLE DRUG DELIVERY FORMULATIONS, BY PRODUCT TYPE
6.4.2.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
6.4.2.2. NOVEL DRUG DELIVERY FORMULATIONS
6.4.2.3. LONG ACTING INJECTION FORMULATIONS
6.5. OPTHALMIC DRUG DELIVERY, BY PRODUCT TYPE
6.5.1. OCCULAR DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.5.1.1. DRUG COATED CONTACT LENSES
6.5.1.2. OCCULAR INSERTS
6.5.2. OCCULAR DRUG DELIVERY FORMULATIONS, BY FORM
6.5.2.1. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
6.5.2.1.1. EYE DROPS
6.5.2.1.2. SPRAYS
6.5.2.2. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
6.5.2.2.1. GELS
6.5.2.2.2. OINTMENTS
6.6. NASAL DRUG DELIVERY, BY PRODUCT TYPE
6.6.1. NASAL DROPS
6.6.2. NASAL SPRAYS
6.6.3. NASAL POWDERS
6.6.4. NASAL GELS
6.7. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
6.7.1. TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.7.1.1. TRANSDERMAL PATCHES
6.7.1.2. TRANSDERMAL GELS
6.7.2. TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM
6.7.2.1. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.7.2.1.1. SOLUTIONS
6.7.2.1.2. SUSPENSIONS
6.7.2.2. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.7.2.2.1. GELS
6.7.2.2.2. CREAMS
6.7.2.2.3. OINTMENTS
6.7.2.2.4. PASTES
6.7.2.2.5. LOTIONS
6.7.2.3. SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.7.2.3.1. SUPPOSITORIES
6.7.2.3.2. POWDERS
6.8. IMPLANTABLE DRUG DELIVERY, BY PRODUCT TYPE
6.8.1. ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
6.8.2. PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
6.9. TRANSMUCOSAL DRUG DELIVERY, BY PRODUCT TYPE
6.9.1. ORAL TRANSMUCOSAL DRUG DELIVERY, BY TYPE
6.9.1.1. BUCCAL DRUG DELIVERY
6.9.1.2. SUBLINGUAL DRUG DELIVERY
6.9.2. OTHER TRANSMUCOSAL DRUG DELIVERY, BY TYPE
6.9.2.1. RECTAL TRANSMUCOSAL DRUG DELIVERY
6.9.2.2. TRANSMUCOSAL TRANSMUCOSAL DRUG DELIVERY
7 DRUG DELIVERY DEVICES MARKET, BY END-USER
7.1. OVERVIEW
7.2. HOSPITALS
7.3. HOME HEALTHCARE
7.4. CLINICS
7.5. COMMUNITY HEALTHCARE
7.6. OTHERS
8 DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. HOSPITAL PHARMACIES
8.3. PHARMACY STORES
8.4. DIRECT TENDERS
8.5. ONLINE PHARMACY
9 DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY
9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
9.1.1. NORTH AMERICA
9.1.1.1. U.S.
9.1.1.2. CANADA
9.1.1.3. MEXICO
9.1.2. EUROPE
9.1.2.1. GERMANY
9.1.2.2. FRANCE
9.1.2.3. U.K.
9.1.2.4. ITALY
9.1.2.5. SPAIN
9.1.2.6. RUSSIA
9.1.2.7. TURKEY
9.1.2.8. BELGIUM
9.1.2.9. NETHERLANDS
9.1.2.10. SWITZERLAND
9.1.2.11. REST OF EUROPE
9.1.3. ASIA-PACIFIC (APAC)
9.1.3.1. JAPAN
9.1.3.2. CHINA
9.1.3.3. SOUTH KOREA
9.1.3.4. INDIA
9.1.3.5. AUSTRALIA
9.1.3.6. SINGAPORE
9.1.3.7. THAILAND
9.1.3.8. MALAYSIA
9.1.3.9. INDONESIA
9.1.3.10. PHILIPPINES
9.1.3.11. REST OF APAC
9.1.4. LATIN AMERICA
9.1.4.1. BRAZIL
9.1.4.2. REST OF LATIN AMERICA
9.1.5. MIDDLE EAST AND AFRICA
9.1.5.1. SOUTH AFRICA
9.1.5.2. REST OF MIDDLE EAST AND AFRICA
9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
10 DRUG DELIVERY DEVICES MARKET: COMPETITIVE LANDSCAPE
10.1. GLOBAL DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.2. U.S. DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.3. EUROPE DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.4. APAC DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
11 DRUG DELIVERY DEVICES MARKET, COMPANY PROFILES
11.1 BAYER AG
11.1.1 COMPANY OVERVIEW
11.1.2 REVENUE ANALYSIS
11.1.3 PRODUCT PORTFOLIO
11.1.4 RECENT DEVELOPEMENTS
11.1.5 DATA BRIDGE ANALYSIS
11.2 JOHNSON & JOHNSON
11.2.1 COMPANY OVERVIEW
11.2.2 REVENUE ANALYSIS
11.2.3 PRODUCT PORTFOLIO
11.2.4 RECENT DEVELOPEMENTS
11.2.5 DATA BRIDGE ANALYSIS
11.3 NOVARTIS AG
11.3.1 COMPANY OVERVIEW
11.3.2 REVENUE ANALYSIS
11.3.3 PRODUCT PORTFOLIO
11.3.4 RECENT DEVELOPEMENTS
11.3.5 DATA BRIDGE ANALYSIS
11.4 PFIZER, INC.
11.4.1 COMPANY OVERVIEW
11.4.2 REVENUE ANALYSIS
11.4.3 PRODUCT PORTFOLIO
11.4.4 RECENT DEVELOPEMENTS
11.4.5 DATA BRIDGE ANALYSIS
11.5 F. HOFFMANN-LA ROCHE AG
11.5.1 COMPANY OVERVIEW
11.5.2 REVENUE ANALYSIS
11.5.3 PRODUCT PORTFOLIO
11.5.4 RECENT DEVELOPEMENTS
11.5.5 DATA BRIDGE ANALYSIS
11.6 GLAXOSMITHKLINE PLC
11.6.1 COMPANY OVERVIEW
11.6.2 REVENUE ANALYSIS
11.6.3 PRODUCT PORTFOLIO
11.6.4 RECENT DEVELOPEMENTS
11.6.5 DATA BRIDGE ANALYSIS
11.7 MERCK & CO.
11.7.1 COMPANY OVERVIEW
11.7.2 REVENUE ANALYSIS
11.7.3 PRODUCT PORTFOLIO
11.7.4 RECENT DEVELOPEMENTS
11.7.5 DATA BRIDGE ANALYSIS
11.8 ANTARES PHARMA, INC.
11.8.1 COMPANY OVERVIEW
11.8.2 REVENUE ANALYSIS
11.8.3 PRODUCT PORTFOLIO
11.8.4 RECENT DEVELOPEMENTS
11.8.5 DATA BRIDGE ANALYSIS
11.9 3M
11.9.1 COMPANY OVERVIEW
11.9.2 REVENUE ANALYSIS
11.9.3 PRODUCT PORTFOLIO
11.9.4 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.10 SANOFI
11.10.1 COMPANY OVERVIEW
11.10.2 REVENUE ANALYSIS
11.10.3 PRODUCT PORTFOLIO
11.10.4 RECENT DEVELOPEMENTS
11.10.5 DATA BRIDGE ANALYSIS
11.11 NEMERA
11.11.1 COMPANY OVERVIEW
11.11.2 REVENUE ANALYSIS
11.11.3 PRODUCT PORTFOLIO
11.11.4 RECENT DEVELOPEMENTS
11.11.5 DATA BRIDGE ANALYSIS
12 APPENDIX
13 DISCLAIMER

1 INTRODUCTION
    1.1. OVERVIEW OF THE DRUG DELIVERY DEVICES MARKET
    1.2. CURRENCY AND PRICING
    1.3. LIMITATION
    1.4. MARKETS COVERED
2 RESEARCH METHODOLOGY
    2.1. MARKETS IN DRUG DELIVERY DEVICES MARKET
    2.2. GEOGRAPHICAL SCOPE
    2.3. YEARS CONSIDERED IN THE STUDY
    2.4. CURRENCY AND PRICING
    2.5. RESEARCH METHODOLOGY
      2.5.1. MARKET CRACKDOWN APPROACH
      2.5.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
      2.5.3. DATA TRIANGULATION
    2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
    2.7. SECONDARY SOURCES
    2.8. ASSUMPTIONS
3 MARKET OVERVIEW
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
    6.1. OVERVIEW
    6.2. ORAL DRUG DELIVERY, BY FORM
      6.2.1. SOLID ORAL DRUGS, BY PRODUCT TYPE
6.2.2.1. TABLETS
6.2.2.2. CAPSULES
6.2.2.3. POWDER
6.2.2.4. PILLS
      6.2.2. LIQUID ORAL DRUGS, BY PRODUCT TYPE
6.2.2.1. SOLUTIONS
6.2.2.2. SYRUPS
      6.2.2. SEMI SOLID ORAL DRUGS, BY PRODUCT TYPE
6.2.2.1. GELS
6.2.2.2. EMULSIONS
6.2.2.3. ELIXIRS
    6.3. PULMONARY DRUG DELIVERY, BY PRODUCT TYPE
      6.3.1. METERED DOSE INHALERS (MDI)
      6.3.2. DRY POWDER INHALERS (DPI)
      6.3.3. NEBULIZERS
6.3.3.1. JET NEBULIZERS
6.3.3.2. ULTRASONIC NEBULIZERS
6.3.3.3. SOFT MIST NEBULIZERS
    6.4. INJECTABLE DRUG DELIVERY, BY PRODUCT TYPE
      6.4.1. INJECTABLE DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.4.1.1. CONVENTIONALS INJECTABLES, BY MATERIAL
6.4.1.1.1. GLASS
6.4.1.1.2. PLASTIC
6.4.2.2. CONVENTIONALS INJECTABLES, BY PRODUCT TYPE
6.4.2.2.1. FILLABLE
6.4.2.2.2. PRE-FILLED
6.4.3.3. CONVENTIONALS INJECTABLES, BY USABILITY
6.4.3.3.1. REUSABLE SYRIGES
6.4.3.3.2. DISPOSABLE SYRINGES
6.4.3.4. SELF INJECTION DEVICES
6.4.3.5. NEEDLE FREE INJECTORS
6.4.3.6. AUTOINJECTORS
6.4.3.7. PEN INJECTORS
6.4.3.8. WEARABLE INJCTORS
6.4.3.9. OTHERS
      6.4.2. INJECTABLE DRUG DELIVERY FORMULATIONS, BY PRODUCT TYPE
6.4.2.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
6.4.2.2. NOVEL DRUG DELIVERY FORMULATIONS
6.4.2.3. LONG ACTING INJECTION FORMULATIONS
    6.5. OPTHALMIC DRUG DELIVERY, BY PRODUCT TYPE
      6.5.1. OCCULAR DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.5.1.1. DRUG COATED CONTACT LENSES
6.5.1.2. OCCULAR INSERTS
      6.5.2. OCCULAR DRUG DELIVERY FORMULATIONS, BY FORM
6.5.2.1. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
6.5.2.1.1. EYE DROPS
6.5.2.1.2. SPRAYS
6.5.2.2. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
6.5.2.2.1. GELS
6.5.2.2.2. OINTMENTS
    6.6. NASAL DRUG DELIVERY, BY PRODUCT TYPE
      6.6.1. NASAL DROPS
      6.6.2. NASAL SPRAYS
      6.6.3. NASAL POWDERS
      6.6.4. NASAL GELS
    6.7. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
      6.7.1. TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.7.1.1. TRANSDERMAL PATCHES
6.7.1.2. TRANSDERMAL GELS
      6.7.2. TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM
6.7.2.1. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.7.2.1.1. SOLUTIONS
6.7.2.1.2. SUSPENSIONS
6.7.2.2. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.7.2.2.1. GELS
6.7.2.2.2. CREAMS
6.7.2.2.3. OINTMENTS
6.7.2.2.4. PASTES
6.7.2.2.5. LOTIONS
6.7.2.3. SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.7.2.3.1. SUPPOSITORIES
6.7.2.3.2. POWDERS
    6.8. IMPLANTABLE DRUG DELIVERY, BY PRODUCT TYPE
      6.8.1. ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
      6.8.2. PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
    6.9. TRANSMUCOSAL DRUG DELIVERY, BY PRODUCT TYPE
      6.9.1. ORAL TRANSMUCOSAL DRUG DELIVERY, BY TYPE
6.9.1.1. BUCCAL DRUG DELIVERY
6.9.1.2. SUBLINGUAL DRUG DELIVERY
      6.9.2. OTHER TRANSMUCOSAL DRUG DELIVERY, BY TYPE
6.9.2.1. RECTAL TRANSMUCOSAL DRUG DELIVERY
6.9.2.2. TRANSMUCOSAL TRANSMUCOSAL DRUG DELIVERY
7 DRUG DELIVERY DEVICES MARKET, BY END-USER
    7.1. OVERVIEW
    7.2. HOSPITALS
    7.3. HOME HEALTHCARE
    7.4. CLINICS
    7.5. COMMUNITY HEALTHCARE
    7.6. OTHERS
8 DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL
    8.1. OVERVIEW
    8.2. HOSPITAL PHARMACIES
    8.3. PHARMACY STORES
    8.4. DIRECT TENDERS
    8.5. ONLINE PHARMACY
9 DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY
    9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
9.1.1. NORTH AMERICA
9.1.1.1. U.S.
9.1.1.2. CANADA
9.1.1.3. MEXICO
9.1.2. EUROPE
9.1.2.1. GERMANY
9.1.2.2. FRANCE
9.1.2.3. U.K.
9.1.2.4. ITALY
9.1.2.5. SPAIN
9.1.2.6. RUSSIA
9.1.2.7. TURKEY
9.1.2.8. BELGIUM
9.1.2.9. NETHERLANDS
9.1.2.10. SWITZERLAND
9.1.2.11. REST OF EUROPE
9.1.3. ASIA-PACIFIC (APAC)
9.1.3.1. JAPAN
9.1.3.2. CHINA
9.1.3.3. SOUTH KOREA
9.1.3.4. INDIA
9.1.3.5. AUSTRALIA
9.1.3.6. SINGAPORE
9.1.3.7. THAILAND
9.1.3.8. MALAYSIA
9.1.3.9. INDONESIA
9.1.3.10. PHILIPPINES
9.1.3.11. REST OF APAC
9.1.4. LATIN AMERICA
9.1.4.1. BRAZIL
9.1.4.2. REST OF LATIN AMERICA
9.1.5. MIDDLE EAST AND AFRICA
9.1.5.1. SOUTH AFRICA
9.1.5.2. REST OF MIDDLE EAST AND AFRICA
    9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
10 DRUG DELIVERY DEVICES MARKET: COMPETITIVE LANDSCAPE
    10.1. GLOBAL DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
    10.2. U.S. DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
    10.3. EUROPE DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
    10.4. APAC DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
11 DRUG DELIVERY DEVICES MARKET, COMPANY PROFILES
    11.1 BAYER AG
11.1.1 COMPANY OVERVIEW
11.1.2 REVENUE ANALYSIS
11.1.3 PRODUCT PORTFOLIO
11.1.4 RECENT DEVELOPEMENTS
11.1.5 DATA BRIDGE ANALYSIS
    11.2 JOHNSON & JOHNSON
11.2.1 COMPANY OVERVIEW
11.2.2 REVENUE ANALYSIS
11.2.3 PRODUCT PORTFOLIO
11.2.4 RECENT DEVELOPEMENTS
11.2.5 DATA BRIDGE ANALYSIS
    11.3 NOVARTIS AG
11.3.1 COMPANY OVERVIEW
11.3.2 REVENUE ANALYSIS
11.3.3 PRODUCT PORTFOLIO
11.3.4 RECENT DEVELOPEMENTS
11.3.5 DATA BRIDGE ANALYSIS
    11.4 PFIZER, INC.
11.4.1 COMPANY OVERVIEW
11.4.2 REVENUE ANALYSIS
11.4.3 PRODUCT PORTFOLIO
11.4.4 RECENT DEVELOPEMENTS
11.4.5 DATA BRIDGE ANALYSIS
    11.5 F. HOFFMANN-LA ROCHE AG
11.5.1 COMPANY OVERVIEW
11.5.2 REVENUE ANALYSIS
11.5.3 PRODUCT PORTFOLIO
11.5.4 RECENT DEVELOPEMENTS
11.5.5 DATA BRIDGE ANALYSIS
    11.6 GLAXOSMITHKLINE PLC
11.6.1 COMPANY OVERVIEW
11.6.2 REVENUE ANALYSIS
11.6.3 PRODUCT PORTFOLIO
11.6.4 RECENT DEVELOPEMENTS
11.6.5 DATA BRIDGE ANALYSIS
    11.7 MERCK & CO.
11.7.1 COMPANY OVERVIEW
11.7.2 REVENUE ANALYSIS
11.7.3 PRODUCT PORTFOLIO
11.7.4 RECENT DEVELOPEMENTS
11.7.5 DATA BRIDGE ANALYSIS
    11.8 ANTARES PHARMA, INC.
11.8.1 COMPANY OVERVIEW
11.8.2 REVENUE ANALYSIS
11.8.3 PRODUCT PORTFOLIO
11.8.4 RECENT DEVELOPEMENTS
11.8.5 DATA BRIDGE ANALYSIS
    11.9 3M
11.9.1 COMPANY OVERVIEW
11.9.2 REVENUE ANALYSIS
11.9.3 PRODUCT PORTFOLIO
11.9.4 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
    11.10 SANOFI
11.10.1 COMPANY OVERVIEW
11.10.2 REVENUE ANALYSIS
11.10.3 PRODUCT PORTFOLIO
11.10.4 RECENT DEVELOPEMENTS
11.10.5 DATA BRIDGE ANALYSIS
    11.11 NEMERA
11.11.1 COMPANY OVERVIEW
11.11.2 REVENUE ANALYSIS
11.11.3 PRODUCT PORTFOLIO
11.11.4 RECENT DEVELOPEMENTS
11.11.5 DATA BRIDGE ANALYSIS
12 APPENDIX
13 DISCLAIMER

captcha
Please enter code
captcha
Please enter code

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

captcha
Please enter code

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$4,200.00
2,820.30
3,864.84
508,788.00
278,516.28
Add To Cart Credit card Logo

Related Reports


Reason to Buy